Cariprazine

證據等級: L5

預測適應症: 10 個

Cariprazine: From Schizophrenia/Bipolar Disorder to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Cariprazine is an atypical antipsychotic acting as a dopamine D3/D2 receptor partial agonist, approved internationally (US, EU) for schizophrenia and bipolar disorder, but not currently registered in Australia. The TxGNN model predicts it may be effective for Retinal Dystrophy with or without Extraocular Anomalies, with no clinical trials and 15 background publications identified — none of which are specific to Cariprazine in this condition. This prediction is currently at hypothesis-generation stage only, and all 10 top-ranked predictions share the same L5 evidence level, warranting a uniform Hold decision at this time.

Quick Overview

Item	Content
Original Indication	Not registered in Australia (overseas approved use: schizophrenia, bipolar disorder)
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	98.70%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in this Evidence Pack. Based on published international literature, Cariprazine (DrugBank DB06016) is a dopamine D3-preferring D2/D3 partial agonist with additional partial agonism at serotonin 5-HT1A receptors and antagonism at 5-HT2B receptors. It is approved by the US FDA and EMA for schizophrenia and bipolar I disorder (manic/mixed episodes and bipolar depression), marketed as Vraylar (US) and Reagila (EU). It has not received TGA approval in Australia.

The theoretical mechanistic link to retinal dystrophy is highly indirect. Dopaminergic signalling is present in retinal amacrine cells, which express D2 and D3 receptors and play a role in light adaptation, retinal circadian rhythmicity, and modulation of photoreceptor function. In principle, a D3/D2 partial agonist could theoretically influence retinal dopamine tone. However, retinal dystrophies such as the condition predicted here are predominantly caused by inherited mutations in photoreceptor-specific or ciliary genes (e.g. RPGR, RPGRIP1, CEP290), with pathology driven by photoreceptor degeneration rather than dopaminergic dysregulation.

This prediction is most likely an artefact of knowledge graph neighbourhood effects — Cariprazine’s neurological drug class node sits in proximity to retinal and ocular disease nodes via shared neurological pathway edges, rather than a direct biological mechanism. The 15 publications retrieved are general ophthalmology reviews and case reports covering orbital infections, congenital ptosis, ocular motility disorders, and related structural conditions; none specifically investigate Cariprazine or any D2/D3 agent in retinal dystrophy. Substantial preclinical mechanistic validation would be required before any clinical consideration of this indication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Note: The 15 publications retrieved are general ophthalmology background references. None are specific to Cariprazine or any dopamine receptor modulator in retinal dystrophy. They were returned based on keyword overlap with extraocular anomalies.

PMID	Year	Type	Journal	Key Findings
38321238	2024	Review	Pediatric Radiology	Differential diagnosis and imaging features of paediatric ocular pathologies, including congenital lesions and retinal conditions
38249493	2023	Review	Taiwan Journal of Ophthalmology	Congenital lens shape anomalies and associated anterior segment dysgenesis
33806565	2021	Research	Int J Mol Sciences	Optic nerve head and retinal abnormalities in congenital fibrosis of extraocular muscles (CFEOM) due to KIF21A/TUBB3 mutations
33447730	2020	Review	Therapeutic Advances in Ophthalmology	Eye involvement across inherited metabolic disorders, including retinal and optic pathway changes
30747268	2019	Review	Neuroradiology	Neuroradiological evaluation and differential diagnosis of ophthalmoplegia
30196776	2018	Review	Journal of Binocular Vision and Ocular Motility	Classification and clinical features of congenital cranial dysinnervation disorders
24932988	2014	Research	American Journal of Ophthalmology	Pathogenesis and proposed treatment of maculopathy associated with cavitary optic disc anomalies
24413161	2014	Case Report	Journal of Neuro-Ophthalmology	Isolated trochlear-oculomotor synkinesis in a child — rare congenital cranial dysinnervation variant
22241537	2012	Review	Klinische Monatsblätter für Augenheilkunde	Congenital ptosis classification, pathophysiology, and surgical management options
7035111	1981	Review	Documenta Ophthalmologica	Wagner-Stickler syndrome complex: myopia, vitreoretinal degeneration, and associated systemic anomalies

Australia Market Information

Cariprazine is not registered with the Therapeutic Goods Administration (TGA) and has no ARTG entries. It is not commercially available in Australia through standard channels. Prescribers seeking access would need to apply via the TGA’s Special Access Scheme (SAS Category B) or Authorised Prescriber pathway, referencing international product information (US FDA label or EMA Summary of Product Characteristics).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. As Cariprazine is not registered in Australia, prescribers should consult the TGA Special Access Scheme documentation and international prescribing information for current safety data.

Based on international labelling (not Evidence Pack data), Cariprazine carries class-level antipsychotic warnings including tardive dyskinesia, neuroleptic malignant syndrome, metabolic effects, and QT interval considerations. It is metabolised primarily via CYP3A4. These details must be verified against current international product information before any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 top-ranked TxGNN predictions for Cariprazine are rated L5 (model prediction only), with no clinical trial evidence and no drug-specific literature supporting any of the predicted indications — which are predominantly rare structural, genetic, or developmental conditions with no plausible direct dopaminergic mechanistic link. Cariprazine’s absence from the Australian market adds a further regulatory barrier to any repurposing pathway.

To proceed, the following is needed:

Regulatory baseline: Establish a TGA registration or SAS access pathway for Cariprazine in Australia before any repurposing clinical work can be initiated
MOA documentation: Obtain full mechanism of action data from DrugBank (currently a blocking data gap — DG002) and TGA/international PI
Safety profile review: Download and parse international Product Information (FDA/EMA) to complete the blocking safety data gap (DG001) and confirm contraindications, warnings, and drug interactions
Mechanistic prioritisation: If further evaluation is warranted, syndromic myopia (rank 6) represents the most mechanistically coherent candidate — retinal dopamine’s known role in axial elongation and myopia protection is at least biologically grounded — and should be the first indication assessed in a formal scoping review
Preclinical evidence sweep: Commission a targeted literature review specifically combining “cariprazine OR D3 agonist OR D2/D3 partial agonist” with retinal or ocular endpoints, to determine whether any in vitro or animal data exists before committing to clinical hypothesis testing
KG bias assessment: Investigate whether the high TxGNN scores across these rare structural and developmental conditions reflect genuine biological signal or knowledge graph neighbourhood artefacts from proximity of psychiatric drug nodes to neurodevelopmental disease nodes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.